Optimizing Cardiovascular Risk Reduction in Patients with Type 2 Diabetes: Study Design and Rationale of the FIELD Study

Please Note: This CME activity has expired. You may continue to view the material for educational purposes, but this activity is no longer eligible for CME credit.

Course Objectives:
This CME-certified monograph is intended for physicians who treat diabetic patients who exhibit dyslipidemia, including cardiologists, primary care physicians (internists, general/family practice), and endocrinologists.

• Identify cardiovascular risk factors and their clinical consequences in patients with diabetes.
• Identify appropriate pharmacologic treatment options for treating lipid disorders (dyslipidemia) in patients with diabetes.
• Discuss the clinical benefits of reducing cardiovascular risk factors in patients with diabetes.
• Differentiate the therapeutic effects of statin and fibrate therapy in treating lipid disorders.

Accreditation:
Millennium CME Institute, Inc., proudly acknowledges its academic partnership with the UMDNJ—Center for Continuing and Outreach Education in the development of this activity and in the review of the educational content. Millennium CME Institute, Inc., has assumed the responsibility for long-term retention of individual credit records.

This activity was reviewed for relevance, accuracy of content, balance of presentation, and time required for participation by John B. Kostis, MD, FACC, FACP; Harold Kim, MD; and Chirag Shah, MD.

Release Date: August 2005

Expiration Date: August 31, 2006

Millennium CME Institute, Inc., is accredited by the ACCME to provide continuing medical education for physicians.

Millennium CME Institute, Inc., designates this educational activity for a maximum of 1.0 Category 1 Credit toward the AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

© Millennium CME Institute, Inc., and UMDNJ—Center for Continuing and Outreach Education. All rights reserved including translation into other languages. No part of this activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval systems, without permission in writing from Millennium CME Institute, Inc., and UMDNJ—Center for Continuing and Outreach Education.

Faculty Disclosure:
Millennium CME Institute, Inc., endorses the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. All faculty are required to disclose any commercial relationships or personal benefit with companies whose products are discussed in educational presentations and with companies who have provided the commercial support for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation, but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

The faculty listed below have declared that they have no relationships to disclose:

• David C. Howard
• Tim I. Robinson
• John T. Warren
• Harold Kim, MD
• Chirag Shah, MD

The faculty listed below have declared the following arrangements and/or affiliations:

Peter H. Jones, MD, FACP: Speakers Bureau—Abbott Laboratories, AstraZeneca; Consultant—Abbott Laboratories, AstraZeneca

John B. Kostis, MD, FACC, FACP: Grant/Research Suppport—Pfizer; Speakers Bureau—AstraZeneca, Aventis, BMS, Merck, Pfizer, Sankyo; Consultant—Berlex, Forest Labs, Pfizer, Sankyo, Schering Plough, Taisho; Scientific Board Member—Pfizer, Schering Plough

Signed Disclosure forms are on file at Millennium CME Institute, Inc.

The opinions expressed in this publication are those of the participating faculty and do not necessarily reflect the opinions or the recommendations of their affiliated institutions; University of Medicine & Dentistry of New Jersey; Millennium CME Institute, Inc.; or any other persons. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this publication should not be used by clinicians without evaluation of their patients’ conditions, assessment of possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with the recommendations of other authorities. This Cardiology Express Report^TM was made possible through an educational grant from Abbott Laboratories.

This CME-certified monograph contains no information of commercial products/ devices that are unlabeled for use or investigational uses of products not yet approved.

Directions:
The learner should read the learning objectives and review the activity in its entirety. After reviewing the material, the learner should complete the Activity Self-assessment Test consisting of a series of multiple-choice questions.

Upon successfully completing this activity as designed and achieving a passing score of 70% or better on the Activity Self-assessment Test, participants will receive a continuing education credit letter awarding the appropriate credit and the Activity Self-assessment Test answers four to six weeks after the receipt of the registration and evaluation materials.

Estimated time to complete this activity as designed is 1.0 hour.

CME Testing Options